

Development of the drug discovery platform based on ^{64}Cu to expedite the R&D of new-generation drugs (LinqMed Inc.)



City	Year of Establishment	Founder	Website
Chiba	2022	Yukie Yoshii Hiroaki Kurihara Hiroki Matsumoto Atsuo Waki	https://www.linqmed.net

Partner VC	Latest round of Fundraising	Valuation
DBJ Capital Co., Ltd.	Series A	Non-Disclosure

Contact Information :

tel : +81-3-6661-7661

e-mai : linqmed@linqmed.co.jp

Website : <https://www.linqmed.net>

○ Business Plan

In this project, a large-scale production of ^{64}Cu will be developed. ^{64}Cu is a unique radioisotope that emits radiation for diagnostic and therapeutic purposes and that easily binds to a variety of molecules. This project will establish Japan's original drug discovery support platform that can rapidly develop "visible" cancer treatments using ^{64}Cu as new-generation drugs. This platform will create a new fundamental for the drug industry.

○ Research Outline

During this project period, we will collaborate with some companies to establish a drug discovery support platform based on ^{64}Cu . Through this, we will develop a large-scale RI production technology that will take on the challenge of creating the next generation pharmaceutical industry infrastructure, and aim to solve economic and social issues.

- (1) Establishment of a large-scale production technology of ^{64}Cu
- (2) Establishment of manufacturing technology for ^{64}Cu with high specific radioactivity
- (3) Long-term stabilization of ^{64}Cu pharmaceuticals

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2023~2025FY	JPY 1,000 million	—